Replication to Enhance Research Impact Initiative

Replication Initiative — Open Funding (Seed)

Funds independent validation of biomedical findings to strengthen reproducibility in research.

The NIH Common Fund's Replication to Enhance Research Impact Initiative funds independent replication of significant preclinical, translational, and technology-development studies from NIH Common Fund programs and other NIH-supported research. The initiative operates through a distinctive two-track partnership model: researchers whose original work is targeted for replication receive support via Notices NOT-RM-24-009 and NOT-RM-24-013 for preparatory activities, primarily the exchange of reagents and protocols; Contract Research Organizations (CROs) receive separate, larger funding to actually conduct the independent replication experiments under controlled conditions.

The program is actively awarding. The inaugural Replication Prize ceremony was held on May 13, 2026, recognizing researchers who demonstrated distinguished contributions to replication science. The initiative is featured in NIH's Extramural Nexus blog (October 2024), reflecting its role in NIH's broader research integrity agenda. Eligible applicants span a wide range: individuals, universities, nonprofits, research organizations, and for-profit companies (including CROs) may all apply depending on the specific funding opportunity. The overall program budget is not separately itemized in the FY2026 Congressional Justification.

Current open funding opportunities should be checked at commonfund.nih.gov/replication-initiative. CROs are a particularly natural fit for the replication execution track, as the program explicitly requires independent parties with no stake in the original findings. Academic researchers whose work is selected for replication can benefit from the reagent-and-protocol exchange support to facilitate the process. The initiative addresses a recognized gap in biomedical science where high-profile findings often go untested, and NIH's institutional backing gives it unusual leverage to mandate cooperation from original investigators.